Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

adalimumab-atto

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

- PMLiVE

AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma

More than 27,500 people worldwide are affected by the rare form of non-Hodgkin lymphoma

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

- PMLiVE

AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

- PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

- PMLiVE

BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

Approximately 27,000 cases of the disease were diagnosed in the US in 2024

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

Amgen’s Blincyto granted MHRA approval for new acute lymphoblastic leukaemia indication

Approximately 300 new adult cases of the blood cancer are diagnosed in the UK every year

- PMLiVE

FDA approves Organon’s Vtama cream to treat atopic dermatitis in adults and children

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links